These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 36016257)
41. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974 [TBL] [Abstract][Full Text] [Related]
42. Immunotherapy in endometrial cancer: rationale, practice and perspectives. Cao W; Ma X; Fischer JV; Sun C; Kong B; Zhang Q Biomark Res; 2021 Jun; 9(1):49. PubMed ID: 34134781 [TBL] [Abstract][Full Text] [Related]
43. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy. Gomella LG; Gelpi-Hammerschmidt F; Kundavram C Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724 [TBL] [Abstract][Full Text] [Related]
44. Cancer immunotherapy: the art of targeting the tumor immune microenvironment. da Silva JL; Dos Santos ALS; Nunes NCC; de Moraes Lino da Silva F; Ferreira CGM; de Melo AC Cancer Chemother Pharmacol; 2019 Aug; 84(2):227-240. PubMed ID: 31240384 [TBL] [Abstract][Full Text] [Related]
45. Development of Cancer Immunotherapies. DeLucia DC; Lee JK Cancer Treat Res; 2022; 183():1-48. PubMed ID: 35551655 [TBL] [Abstract][Full Text] [Related]
46. Harnessing the immune system to improve cancer therapy. Papaioannou NE; Beniata OV; Vitsos P; Tsitsilonis O; Samara P Ann Transl Med; 2016 Jul; 4(14):261. PubMed ID: 27563648 [TBL] [Abstract][Full Text] [Related]
47. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784 [TBL] [Abstract][Full Text] [Related]
48. The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. Khalil DN; Budhu S; Gasmi B; Zappasodi R; Hirschhorn-Cymerman D; Plitt T; De Henau O; Zamarin D; Holmgaard RB; Murphy JT; Wolchok JD; Merghoub T Adv Cancer Res; 2015; 128():1-68. PubMed ID: 26216629 [TBL] [Abstract][Full Text] [Related]
49. Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet? Taha T; Reiss A; Amit A; Perets R BioDrugs; 2020 Dec; 34(6):749-762. PubMed ID: 33141420 [TBL] [Abstract][Full Text] [Related]
50. Immunotherapy in prostate cancer: new horizon of hurdles and hopes. Tsaur I; Brandt MP; Juengel E; Manceau C; Ploussard G World J Urol; 2021 May; 39(5):1387-1403. PubMed ID: 33106940 [TBL] [Abstract][Full Text] [Related]
51. Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy. Amir Taghavi B; Alizadeh N; Saeedi H; Karim Ahangar N; Derakhshani A; Hajiasgharzadeh K; Silvestris N; Baradaran B; Brunetti O Molecules; 2022 May; 27(11):. PubMed ID: 35684481 [TBL] [Abstract][Full Text] [Related]
52. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer. Zeng Z; Yang B; Liao Z Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136 [TBL] [Abstract][Full Text] [Related]
53. Immunotherapy for pancreatic cancer: A 2020 update. Schizas D; Charalampakis N; Kole C; Economopoulou P; Koustas E; Gkotsis E; Ziogas D; Psyrri A; Karamouzis MV Cancer Treat Rev; 2020 Jun; 86():102016. PubMed ID: 32247999 [TBL] [Abstract][Full Text] [Related]
54. Immunotherapy for anaplastic thyroid carcinoma: the present and future. Lu X; Bao L; Pan Z; Ge M Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 50(6):675-684. PubMed ID: 35347912 [TBL] [Abstract][Full Text] [Related]
55. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies? Hosseinkhani N; Derakhshani A; Kooshkaki O; Abdoli Shadbad M; Hajiasgharzadeh K; Baghbanzadeh A; Safarpour H; Mokhtarzadeh A; Brunetti O; Yue SC; Silvestris N; Baradaran B Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167514 [TBL] [Abstract][Full Text] [Related]
56. Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis. Oh SJ; Lee J; Kim Y; Song KH; Cho E; Kim M; Jung H; Kim TW Immune Netw; 2020 Feb; 20(1):e7. PubMed ID: 32158595 [TBL] [Abstract][Full Text] [Related]
57. Current Immunotherapeutic Approaches for Malignant Gliomas. Han MH; Kim CH Brain Tumor Res Treat; 2022 Jan; 10(1):1-11. PubMed ID: 35118842 [TBL] [Abstract][Full Text] [Related]
58. The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy. van Meir H; Kenter GG; Burggraaf J; Kroep JR; Welters MJ; Melief CJ; van der Burg SH; van Poelgeest MI Anticancer Agents Med Chem; 2014 Feb; 14(2):190-203. PubMed ID: 24237223 [TBL] [Abstract][Full Text] [Related]
59. New Immunotherapy Strategies in Breast Cancer. Yu LY; Tang J; Zhang CM; Zeng WJ; Yan H; Li MP; Chen XP Int J Environ Res Public Health; 2017 Jan; 14(1):. PubMed ID: 28085094 [TBL] [Abstract][Full Text] [Related]